Top Markets
#1 BSquared Network BSquared Network +96.19%
#2 Akedo Akedo +33.46%
#3 Derive Derive +33.21%
#4 DogBull DogBull +31.24%
#5 Zama Zama +27.76%
#6 Arweave Arweave +24.51%
#7 MetaDAO MetaDAO +20.80%
#8 Harmony Harmony +16.97%
#9 Cortex Cortex +16.52%
#10 Synapse Synapse +16.16%
Coin of the day
BSquared Network BSquared Network
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Kedudukan dalam Saham #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Harga Saham
$150.78
Disegerakkan terakhir: 2026-09-18
Modal Pasaran
$187.20B
Perubahan (1 hari)
-0.08%
Perubahan (1 tahun)
32.15%
Negara
US
Perdagangan Gilead Sciences, Inc. (GILD)

Kategori

Healthcare
Nisbah P/E bagi Gilead Sciences, Inc. (GILD)
Nisbah P/E pada September 2026 TTM: -56.31
Menurut laporan kewangan dan harga saham terkini Gilead Sciences, Inc., nisbah P/E semasa (TTM) ialah -56.31. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 239.97.
Sejarah nisbah P/E bagi Gilead Sciences, Inc. dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -56.31 -413.89%
2025 17.94 -92.52%
2024 239.97 1,244.63%
2023 17.85 -23.94%
2022 23.46 60.15%
2021 14.65 -97.54%
2020 595.39 3,785.82%
2019 15.32 2.95%
2018 14.88 -26.44%
2017 20.23 184.87%
2016 7.10 -13.19%
2015 8.18 -30.99%
2014 11.86 -68.24%
2013 37.33 73.94%
2012 21.46 89.77%
2011 11.31 5.77%
2010 10.69 -28.01%
2009 14.85 -37.57%
2008 23.79 -10.08%
2007 26.46 -205.64%
2006 -25.05 -185.37%
2005 29.34 -12.80%
2004 33.65 -120.66%
2003 -162.89 -276.64%
2002 92.22 -22.94%
2001 119.67 -280.07%
2000 -66.46 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 38.12 -167.69%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.79 -154.68%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 73.73 -230.93%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -139.51%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 114.95 -304.14%
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.